Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George R Simon

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 20, 2011
The role of molecular analyses in the era of personalized therapy for advanced NSCLCNichole T Tanner, Nicholas J Pastis, Carol Sherman, et al.
Clinical Lung Cancer|August 8, 2013
Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancerGeorge R Simon, Christian Manegold, Scott S Barker, et al.
Oncoimmunology|June 27, 2013
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancerBen C Creelan, Scott Antonia, Gerold Bepler, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 1, 2006
Malignant pleural mesothelioma: a comprehensive reviewRoohi Ismail-Khan, Lary A Robinson, Charles C Williams, et al.
Oncotarget|April 12, 2014
Molecular pathways and therapeutic targets in lung cancerEmma Shtivelman, Thomas Hensing, George R Simon, et al.
Cancer Control : Journal of the Moffitt Cancer Center|December 21, 2013
Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgeryCharu Aggarwal, Linna Li, Hossein Borghaei, et al.
Cancer|October 27, 2011
Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysisGeorge R Simon, Michael J Schell, Mubeena Begum, et al.
Chest|October 6, 2007
Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)David J Samson, Jerome Seidenfeld, George R Simon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2012
Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selectionNichole T Tanner, Mario Gomez, Chelsea Rainwater, et al.
Immunotherapy|February 5, 2019
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysisAndrew M Frederickson, Stella Arndorfer, Ina Zhang, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Lung Cancer (Amsterdam, Netherlands)|December 20, 2011
The role of molecular analyses in the era of personalized therapy for advanced NSCLCNichole T Tanner, Nicholas J Pastis, Carol Sherman, et al.
Clinical Lung Cancer|August 8, 2013
Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancerGeorge R Simon, Christian Manegold, Scott S Barker, et al.
Oncoimmunology|June 27, 2013
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancerBen C Creelan, Scott Antonia, Gerold Bepler, et al.
Cancer Control : Journal of the Moffitt Cancer Center|November 1, 2006
Malignant pleural mesothelioma: a comprehensive reviewRoohi Ismail-Khan, Lary A Robinson, Charles C Williams, et al.
Oncotarget|April 12, 2014
Molecular pathways and therapeutic targets in lung cancerEmma Shtivelman, Thomas Hensing, George R Simon, et al.
Cancer Control : Journal of the Moffitt Cancer Center|December 21, 2013
Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgeryCharu Aggarwal, Linna Li, Hossein Borghaei, et al.
Cancer|October 27, 2011
Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysisGeorge R Simon, Michael J Schell, Mubeena Begum, et al.
Chest|October 6, 2007
Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)David J Samson, Jerome Seidenfeld, George R Simon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2012
Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selectionNichole T Tanner, Mario Gomez, Chelsea Rainwater, et al.
Immunotherapy|February 5, 2019
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysisAndrew M Frederickson, Stella Arndorfer, Ina Zhang, et al.
Pageof 8